Drug Use Investigation of Kovaltry in Hemophilia A Patients

Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment

NCT02396862 ·Status: COMPLETED

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

NCT00629837 ·Status: COMPLETED ·Phase: PHASE1

Prophylaxis Versus on Demand Treatment for Children With Hemophilia A

NCT01810666 ·Status: COMPLETED ·Phase: PHASE4

Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo

NCT06831734 ·Status: ENROLLING_BY_INVITATION

Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors

NCT02453542 ·Status: RECRUITING

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

NCT01775618 ·Status: COMPLETED ·Phase: PHASE3

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

NCT01184820 ·Status: COMPLETED ·Phase: PHASE1

Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate

NCT02483208 ·Status: COMPLETED ·Phase: PHASE1

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

NCT01580293 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry

NCT03603275 ·Status: TERMINATED

Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia

NCT03996486 ·Status: WITHDRAWN ·Phase: PHASE1

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

NCT00874926 ·Status: COMPLETED

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

NCT06312475 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A

NCT02930317 ·Status: UNKNOWN ·Phase: PHASE3

Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors

NCT01921855 ·Status: COMPLETED ·Phase: PHASE1

Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis

NCT02263066 ·Status: COMPLETED

Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

NCT00768287 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

NCT00782470 ·Status: COMPLETED

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B

NCT02048111 ·Status: WITHDRAWN ·Phase: PHASE3

A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

NCT02571569 ·Status: COMPLETED ·Phase: PHASE1

Prophylaxis Versus On-demand Therapy Through Economic Report

NCT01159587 ·Status: COMPLETED

BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)

NCT00586521 ·Status: COMPLETED ·Phase: PHASE4

Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery

NCT00922597 ·Status: COMPLETED

Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A

NCT01790828 ·Status: COMPLETED

Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A

NCT00621673 ·Status: TERMINATED ·Phase: PHASE4